Pulmonary Disorders II
Eur Heart J. 2022;43:3618-3731)
Group 1 (PAH): Idiopathic, heritable, and drug/toxin-induced PAH, as well as PAH associated with
various diseases, PAH with features of venous/capillary (PVOD/PCH) involvement, or persistent
newborn PH
Group 2: PH caused by left heart disease
Group 3: PH caused by chronic lung disease and/or hypoxia
| d. | Group 4: PH caused by chronic thromboembolic pulmonary hypertension (CTEPH) or other |
|---|
pulmonary artery obstructions
Group 5: PH with unclear multifactorial mechanisms
PH is defined as a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest as measured
by right heart catheterization. PH is a term that encompasses all 5 groups and is not specific to any
single group. (Eur Respir J. 2024;64(4):2401324; Eur Heart J. 2022;43:3618-3731)
Hemodynamic definitions of PH (Eur Heart J 2022;43:3618-731; Eur Respir J. 2024;64(4):2401324)
Groups 1, 3, 4, and 5: Precapillary PH defined as mPAP greater than 20 mmHg, pulmonary
capillary wedge pressure (PCWP) less than or equal to 15 mm Hg, and PVR greater than 2
Wood units
ii.
Group 2: Isolated postcapillary PH defined as mPAP greater than 20 mmHg, PCWP greater
than 15 mm Hg, and PVR less than or equal to 2 Wood units
iii.
Group 2: Combined pre- and postcapillary PH defined as mPAP greater than 20 mmHg, PCWP
greater than 15 mm Hg, and PVR greater than 2 Wood units
Initial symptoms of group 1 (PAH) are nonspecific.
Common symptoms: Fatigue, shortness of breath with exertion, chest pain, and syncope
Less common presentations: Dry cough, nausea, and vomiting
of such symptoms. This list is not complete, and additional tests may be performed based on patient-
specific factors.
Electrocardiogram
BNP/N-terminal proβbrain natriuretic peptide (NT-proBNP)
Chest radiograph
| d. | Pulmonary function tests |
|---|
ABG
Echocardiogram is used to predict likelihood of PH based on specific findings
Peak tricuspid regurgitation velocity (pTRV) is a key factor in suggesting the probability of
PH, but it is only a suggestive factor and should not be used independently to predict PH.
Guidelines differ in their recommendation for threshold of pTRV to suggest PH, with newer
guidelines using > 2.8 m/second.
ii.
Various measurements in the ventricles, pulmonary artery, inferior vena cava, and right atrium
contribute to the determination of PH diagnosis.
iii.
Echocardiogram should not be used independently to diagnose PH.
Ventilation/perfusion scan can be used to identify possible group 4 PH (CTEPH).
Computed tomography (CT) or CT pulmonary angiography (if CTEPH is suspected)
Cardiac magnetic resonance imaging can provide noninvasive prognostic assessment of the right
heart initially and at follow up.
Right heart catheterization is required to confirm diagnosis.
| k. | Perform vasoreactivity testing if appropriate. |
|---|